Publications

  1. Opyrchal M, Salisbury JL, Iankov I, Goetz MP, McCubrey J, Gambino MW, Malatino L, Puccia G, Ingle JN, Galanis E, D'Assoro AB. Inhibition of Cdk2 kinase activity selectively targets the CD44(+)/CD24(-)/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells. Int J Oncol. 2014 Sep; 45(3):1193-9. Epub 2014 Jun 25.
    View PubMed
  2. D'Assoro AB, Liu T, Quatraro C, Amato A, Opyrchal M, Leontovich A, Ikeda Y, Ohmine S, Lingle W, Suman V, Ecsedy J, Iankov I, Di Leonardo A, Ayers-Inglers J, Degnim A, Billadeau D, McCubrey J, Ingle J, Salisbury JL, Galanis E. The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERalpha(+) breast cancer cells. Oncogene. 2014 Jan 30; 33(5):599-610. Epub 2013 Jan 21.
    View PubMed
  3. Opyrchal M, Salisbury JL, Zhang S, McCubrey J, Hawse J, Goetz MP, Lomberk GA, Haddad T, Degnim A, Lange C, Ingle JN, Galanis E, D'Assoro AB. Aurora-A Mitotic Kinase Induces Endocrine Resistance through Down-Regulation of ERalpha Expression in Initially ERalpha+ Breast Cancer Cells. PLoS One. 2014; 9(5):e96995. Epub 2014 May 09.
    View PubMed
  4. Domingo Musibay E, Allen C, Kurokawa C, Hardcastle JJ, Aderca I, Msaouel P, Bansal A, Jiang H, DeGrado TR, Galanis E. Measles edmonston vaccine strain derivatives have potent oncolytic activity against osteosarcoma. Mol Oncol [submitted]. 2014.
  5. Alexander BM, Galanis E, Ligon KL, Ballman KV, Boyett JM, Cloughesy TF, Degroot J, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelson T, Mischel PS, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Yung WKA, Berry DA, Wen PY. Brain Malignancy Steering Committee Clinical Trials Planning Workshop: report from the Targeted Therapies Working Group. Neuro Oncol. 2014.
  6. Johnson D, Galanis E. Medical Management of High-Grade Astrocytoma: Current and Emerging Therapies. Sem Oncol. 2014.
  7. Opyrchal M, Allen C, Msaouel P, Iankov I, Galanis E. Inhibition of Rho-associated coiled-coil-forming kinase increases efficacy of measles virotherapy. Cancer Gene Ther. 2013 Nov; 20(11):630-7. Epub 2013 Oct 25.
    View PubMed
  8. Iankov ID, Federspiel MJ, Galanis E. Measles virus expressed Helicobacter pylori neutrophil-activating protein significantly enhances the immunogenicity of poor immunogens. Vaccine. 2013 Oct 1; 31(42):4795-801. Epub 2013 Aug 12.
    View PubMed
  9. Galanis E, Anderson SK, Lafky JM, Uhm JH, Giannini C, Kumar SK, Kimlinger TK, Northfelt DW, Flynn PJ, Jaeckle KA, Kaufmann TJ, Buckner JC. Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. Clin Cancer Res. 2013 Sep 1; 19(17):4816-23. Epub 2013 Jul 05.
    View PubMed
  10. Leontovich AA, Salisbury JL, Veroux M, Tallarita T, Billadeau D, McCubrey J, Ingle J, Galanis E, D'Assoro AB. Inhibition of Cdk2 activity decreases Aurora-A kinase centrosomal localization and prevents centrosome amplification in breast cancer cells. Oncol Rep. 2013 May; 29(5):1785-8. Epub 2013 Feb 27.
    View PubMed
  11. Allen C, Opyrchal M, Aderca I, Schroeder MA, Sarkaria JN, Domingo E, Federspiel MJ, Galanis E. Oncolytic measles virus strains have significant antitumor activity against glioma stem cells. Gene Ther. 2013 Apr; 20(4):444-9. Epub 2012 Aug 23.
    View PubMed
  12. Msaouel P, Opyrchal M, Domingo Musibay E, Galanis E. Oncolytic measles virus strains as novel anticancer agents. Expert Opin Biol Ther. 2013 Apr; 13(4):483-502. Epub 2013 Jan 06.
    View PubMed
  13. Iankov ID, Penheiter AR, Griesmann GE, Carlson SK, Federspiel MJ, Galanis E. Neutralization capacity of measles virus H protein specific IgG determines the balance between antibody-enhanced infectivity and protection in microglial cells. Virus Res. 2013 Mar; 172(1-2):15-23. Epub 2012 Dec 21.
    View PubMed
  14. Johnson DR, Galanis E. Incorporation of prognostic and predictive factors into glioma clinical trials. Curr Oncol Rep. 2013 Feb; 15(1):56-63.
    View PubMed
  15. Mader EK, Butler G, Dowdy SC, Mariani A, Knutson KL, Federspiel MJ, Russell SJ, Galanis E, Dietz AB, Peng KW. Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med. 2013; 11:20. Epub 2013 Jan 24.
    View PubMed
  16. Gorlia T, Wenting W, Wang M, Baumert B, Mehta M, Buckner JC, Shaw E, Brown P, Stupp R, Galanis E, Lacombe D, van den. New validated prognostic models and prognostic calculators in patients with low grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials. Neuro Oncol. 2013; 15(11):1568-1579.
    View PubMed
  17. Huveldt D, Lewis-Tuffin LJ, Carlson BL, Schroeder MA, Rodriguez F, Giannini C, Galanis E, Sarkaria JN, Anastasiadis PZ. Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion. PLoS One. 2013; 8(2):e56505. Epub 2013 Feb 14.
    View PubMed
  18. Iankov ID, Penheiter AR, Carlson SK, Galanis E. Development of monoclonal antibody-based immunoassays for detection of Helicobacter pylori neutrophil-activating protein. J Immunol Methods. 2012 Oct 31; 384(1-2):1-9. Epub 2012 Jun 28.
    View PubMed
  19. Dickson AM, Anderson JR, Barnhart MD, Sokoloski KJ, Oko L, Opyrchal M, Galanis E, Wilusz CJ, Morrison TE, Wilusz J. Dephosphorylation of HuR protein during alphavirus infection is associated with HuR relocalization to the cytoplasm. J Biol Chem. 2012 Oct 19; 287(43):36229-38. Epub 2012 Aug 22.
    View PubMed
  20. Nuovo GJ, Garofalo M, Valeri N, Roulstone V, Volinia S, Cohn DE, Phelps M, Harrington KJ, Vile R, Melcher A, Galanis E, Sehl S, Adair R, Scott K, Rose A, Toogood G, Coffey MC. Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. Mod Pathol. 2012 Oct; 25(10):1333-44. Epub 2012 Jun 15.
    View PubMed
  21. Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, Nevala WK, Thompson MA, Lewis JE, Rumilla KM, Roulstone V, Harrington K, Linette GP, Maples WJ, Coffey M, Zwiebel J, Kendra K. Phase II trial of intravenous administration of Reolysin((R)) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther. 2012 Oct; 20(10):1998-2003. Epub 2012 Aug 07.
    View PubMed
  22. Msaouel P, Iankov ID, Dispenzieri A, Galanis E. Attenuated oncolytic measles virus strains as cancer therapeutics. Curr Pharm Biotechnol. 2012 Jul; 13(9):1732-41.
    View PubMed
  23. Leontovich AA, Zhang S, Quatraro C, Iankov I, Veroux PF, Gambino MW, Degnim A, McCubrey J, Ingle J, Galanis E, D'Assoro AB. Raf-1 oncogenic signaling is linked to activation of mesenchymal to epithelial transition pathway in metastatic breast cancer cells. Int J Oncol. 2012 Jun; 40(6):1858-64. Epub 2012 Mar 19.
    View PubMed
  24. Iankov ID, Allen C, Federspiel MJ, Myers RM, Peng KW, Ingle JN, Russell SJ, Galanis E. Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus. Mol Ther. 2012 Jun; 20(6):1139-47. Epub 2012 Feb 14.
    View PubMed
  25. Johnson DR, Brown PD, Galanis E, Hammack JE. Pilocytic astrocytoma survival in adults: analysis of the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. J Neurooncol. 2012 May; 108(1):187-93. Epub 2012 Feb 25.
    View PubMed
  26. Galanis E, Wu W, Cloughesy T, Lamborn K, Mann B, Wen PY, Reardon DA, Wick W, Macdonald D, Armstrong TS, Weller M, Vogelbaum M, Colman H, Sargent DJ, van den Bent MJ, Gilbert M, Chang S. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol. 2012 May; 13(5):e196-204.
    View PubMed
  27. Ou W, Marino MP, Suzuki A, Joshi B, Husain SR, Maisner A, Galanis E, Puri RK, Reiser J. Specific targeting of human interleukin (il)-13 receptor alpha 2-positive cells with lentiviral vectors displaying il-13. Human Gene Therapy Methods. 2012 Apr; 23(2):137-47.
  28. Studebaker AW, Hutzen B, Pierson CR, Russell SJ, Galanis E, Raffel C. Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluid-disseminated medulloblastoma. Neuro Oncol. 2012 Apr; 14(4):459-70. Epub 2012 Feb 03.
    View PubMed
  29. Opyrchal M, Allen C, Iankov I, Aderca I, Schroeder M, Sarkaria J, Galanis E. Effective radiovirotherapy for malignant gliomas by using oncolytic measles virus strains encoding the sodium iodide symporter (MV-NIS). Hum Gene Ther. 2012 Apr; 23(4):419-27. Epub 2012 Mar 09.
    View PubMed
  30. Friday BB, Anderson SK, Buckner J, Yu C, Giannini C, Geoffroy F, Schwerkoske J, Mazurczak M, Gross H, Pajon E, Jaeckle K, Galanis E. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol. 2012 Feb; 14(2):215-21. Epub 2011 Nov 16.
    View PubMed
  31. Hutzen B, Pierson CR, Russell SJ, Galanis E, Raffel C, Studebaker AW. Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine. BMC Cancer. 2012; 12:508. Epub 2012 Nov 07.
    View PubMed
  32. Msaouel P, Iankov ID, Allen C, Russell SJ, Galanis E. Oncolytic measles virus retargeting by ligand display. Methods Mol Biol. 2012; 797:141-62.
    View PubMed
  33. Sarkaria JN, Galanis E, Wu W, Peller PJ, Giannini C, Brown PD, Uhm JH, McGraw S, Jaeckle KA, Buckner JC. North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2011 Oct 1; 81(2):468-75. Epub 2010 Sep 23.
    View PubMed
  34. Wen PY, Schiff D, Cloughesy TF, Reardon DA, Batchelor TT, Chabner BA, Flaherty K, de Groot JF, Gilbert MR, Galanis E, Chang SM, Schwartz GK, Peereboom D, Mehta MP, Yung WK, Grossman SA, Prados MD, DeAngelis LM. It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol. 2011 Aug 20; 29(24):3211-3. Epub 2011 Jul 18.
    View PubMed
  35. Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol. 2011 Mar; 13(3):353-61. Epub 2011 Feb 09.
    View PubMed
  36. Iankov ID, Haralambieva IH, Galanis E. Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein. Vaccine. 2011 Feb 11; 29(8):1710-20. Epub 2010 Dec 21.
    View PubMed
  37. Galanis E, Wu W, Sarkaria J, Chang SM, Colman H, Sargent D, Reardon DA. Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments. Curr Oncol Rep. 2011 Feb; 13(1):42-9.
    View PubMed
  38. Sarkaria JN, Galanis E, Wu W, Dietz AB, Kaufmann TJ, Gustafson MP, Brown PD, Uhm JH, Rao RD, Doyle L, Giannini C, Jaeckle KA, Buckner JC. Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks. Clin Cancer Res. 2010 Nov 15; 16(22):5573-80. Epub 2010 Oct 04.
    View PubMed
  39. D'Assoro AB, Leontovich A, Amato A, Ayers-Ringler JR, Quatraro C, Hafner K, Jenkins RB, Libra M, Ingle J, Stivala F, Galanis E, Salisbury JL. Abrogation of p53 function leads to metastatic transcriptome networks that typify tumor progression in human breast cancer xenografts. Int J Oncol. 2010 Nov; 37(5):1167-76.
    View PubMed
  40. Galanis E. Therapeutic potential of oncolytic measles virus: promises and challenges. Clin Pharmacol Ther. 2010 Nov; 88(5):620-5. Epub 2010 Sep 29.
    View PubMed
  41. Studebaker AW, Kreofsky CR, Pierson CR, Russell SJ, Galanis E, Raffel C. Treatment of medulloblastoma with a modified measles virus. Neuro Oncol. 2010 Oct; 12(10):1034-42. Epub 2010 May 21.
    View PubMed
  42. Iankov ID, Msaouel P, Allen C, Federspiel MJ, Bulur PA, Dietz AB, Gastineau D, Ikeda Y, Ingle JN, Russell SJ, Galanis E. Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. Breast Cancer Res Treat. 2010 Aug; 122(3):745-54. Epub 2009 Nov 06.
    View PubMed
  43. Jaeckle KA, Ballman KV, Giannini C, Schomberg PJ, Ames MM, Reid JM, McGovern RM, Safgren SL, Galanis E, Uhm JH, Brown PD, Hammack JE, Arusell R, Nikcevich DA, Morton RF, Wender DB, Buckner JC. Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM. J Neurooncol. 2010 Aug; 99(1):73-80. Epub 2010 Jan 9.
    View PubMed
  44. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010 Apr 10; 28(11):1963-72. Epub 2010 Mar 15.
    View PubMed
  45. Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, Kaur JS, Haluska PJ Jr, Aderca I, Zollman PJ, Sloan JA, Keeney G, Atherton PJ, Podratz KC, Dowdy SC, Stanhope CR, Wilson TO, Federspiel MJ, Peng KW, Russell SJ. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 2010 Feb 1; 70(3):875-82. Epub 2010 Jan 26.
    View PubMed
  46. Mavrogenis AF, Mastorakos DP, Triantafyllopoulos G, Sakellariou VI, Galanis EC, Papagelopoulos PJ. Total scapulectomy and constrained reverse total shoulder reconstruction for a Ewing's sarcoma. J Surg Oncol. 2009 Dec 1; 100(7):611-5.
    View PubMed
  47. Mader EK, Maeyama Y, Lin Y, Butler GW, Russell HM, Galanis E, Russell SJ, Dietz AB, Peng KW. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res. 2009 Dec 1; 15(23):7246-55. Epub 2009 Nov 24.
    View PubMed
  48. Msaouel P, Iankov ID, Allen C, Aderca I, Federspiel MJ, Tindall DJ, Morris JC, Koutsilieris M, Russell SJ, Galanis E. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol Ther. 2009 Dec; 17(12):2041-8. Epub 2009 Sep 22.
    View PubMed
  49. Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol. 2009 Sep; 6(9):507-18. Epub 2009 Jul 28.
    View PubMed
  50. Msaouel P, Galanis E, Koutsilieris M. Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology. Expert Opin Investig Drugs. 2009 Sep; 18(9):1297-316.
    View PubMed
  51. Iankov ID, Hillestad ML, Dietz AB, Russell SJ, Galanis E. Converting tumor-specific markers into reporters of oncolytic virus infection. Mol Ther. 2009 Aug; 17(8):1395-403. Epub 2009 May 26.
    View PubMed
  52. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, Richon VM, Scheithauer B, Giannini C, Flynn PJ, Moore DF Jr, Zwiebel J, Buckner JC. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol. 2009 Apr 20; 27(12):2052-8. Epub 2009 Mar 23.
    View PubMed
  53. Santisteban M, Buckner JC, Reid JM, Wu W, Scheithauer BW, Ames MM, Felten SJ, Nikcevich DA, Wiesenfeld M, Jaeckle KA, Galanis E, North Central Cancer Treatment Group. Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results. J Neurooncol. 2009 Apr; 92(2):165-75. Epub 2008 Dec 10.
    View PubMed
  54. Mavrogenis AF, Patapis P, Papaparaskeva KT, Galanis EC, Papagelopoulos PJ. Extraskeletal myxoid chondrosarcoma of the perineum. Orthopedics. 2009 Mar; 32(3):216.
    View PubMed
  55. Msaouel P, Dispenzieri A, Galanis E. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther. 2009 Feb; 11(1):43-53.
    View PubMed
  56. Msaouel P, Iankov ID, Allen C, Morris JC, von Messling V, Cattaneo R, Koutsilieris M, Russell SJ, Galanis E. Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate. 2009 Jan 1; 69(1):82-91.
    View PubMed
  57. Neff BA, Voss SG, Allen C, Schroeder MA, Driscoll CL, Link MJ, Galanis E, Sarkaria JN. Bioluminescent imaging of intracranial vestibular schwannoma xenografts in NOD/SCID mice. Otol Neurotol. 2009 Jan; 30(1):105-11.
    View PubMed
  58. Opyrchal M, Aderca I, Galanis E. Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas. Methods Mol Biol. 2009; 542:705-17.
    View PubMed
  59. Tan TS, Walia T, Galanis E, Goetz MP, Rubin J, Jatoi A. If you hold it off-hours, will they come? Results from a feasibility project intended to stimulate interest in the physician-investigator career path among medical oncology trainees. J Cancer Educ. 2009; 24(3):200-3.
    View PubMed
  60. Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM, Garcia-Vargas J, Sanz-Rodriguez C, Rizvi S. Vorinostat in solid and hematologic malignancies. J Hematol Oncol. 2009; 2:31. Epub 2009 Jul 27.
    View PubMed
  61. Reddi HV, Madde P, Reichert-Eberhardt AJ, Galanis EC, Copland JA, McIver B, Grebe SK, Eberhardt NL. ONYX-411, a conditionally replicative oncolytic adenovirus, induces cell death in anaplastic thyroid carcinoma cell lines and suppresses the growth of xenograft tumors in nude mice. Cancer Gene Ther. 2008 Nov; 15(11):750-7. Epub 2008 Jun 27.
    View PubMed
  62. Allen C, Paraskevakou G, Iankov I, Giannini C, Schroeder M, Sarkaria J, Schroeder M, Puri RK, Russell SJ, Galanis E. Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. Mol Ther. 2008 Sep; 16(9):1556-64. Epub 2008 Jul 29.
    View PubMed
  63. Myers R, Harvey M, Kaufmann TJ, Greiner SM, Krempski JW, Raffel C, Shelton SE, Soeffker D, Zollman P, Federspiel MJ, Blanco M, Galanis E. Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas. Hum Gene Ther. 2008 Jul; 19(7):690-8.
    View PubMed
  64. Liu C, Erlichman C, McDonald CJ, Ingle JN, Zollman P, Iankov I, Russell SJ, Galanis E. Heat shock protein inhibitors increase the efficacy of measles virotherapy. Gene Ther. 2008 Jul; 15(14):1024-34. Epub 2008 Mar 20.
    View PubMed
  65. D'Assoro AB, Busby R, Acu ID, Quatraro C, Reinholz MM, Farrugia DJ, Schroeder MA, Allen C, Stivala F, Galanis E, Salisbury JL. Impaired p53 function leads to centrosome amplification, acquired ERalpha phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenografts. Oncogene. 2008 Jun 26; 27(28):3901-11. Epub 2008 Feb 11.
    View PubMed
  66. Yang L, Clarke MJ, Carlson BL, Mladek AC, Schroeder MA, Decker P, Wu W, Kitange GJ, Grogan PT, Goble JM, Uhm J, Galanis E, Giannini C, Lane HA, James CD, Sarkaria JN. PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. Clin Cancer Res. 2008 Jun 15; 14(12):3993-4001.
    View PubMed
  67. Galanis E, Carlson SK, Foster NR, Lowe V, Quevedo F, McWilliams RR, Grothey A, Jatoi A, Alberts SR, Rubin J. Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer. Mol Ther. 2008 May; 16(5):979-84. Epub 2008 Mar 18.
    View PubMed
  68. Gill P, Litzow M, Buckner J, Arndt C, Moynihan T, Christianson T, Ansell S, Galanis E. High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system. Cancer. 2008 Apr 15; 112(8):1805-11.
    View PubMed
  69. Papagelopoulos PJ, Mavrogenis AF, Savvidou OD, Benetos IS, Galanis EC, Soucacos PN. Pathological fractures in primary bone sarcomas. Injury. 2008 Apr; 39(4):395-403. Epub 2007 Dec 03.
    View PubMed
  70. Allen C, Paraskevakou G, Liu C, Iankov ID, Msaouel P, Zollman P, Myers R, Peng KW, Russell SJ, Galanis E. Oncolytic measles virus strains in the treatment of gliomas. Expert Opin Biol Ther. 2008 Feb; 8(2):213-20.
    View PubMed
  71. Liu C, Sarkaria JN, Petell CA, Paraskevakou G, Zollman PJ, Schroeder M, Carlson B, Decker PA, Wu W, James CD, Russell SJ, Galanis E. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clin Cancer Res. 2007 Dec 1; 13(23):7155-65.
    View PubMed
  72. Paraskevakou G, Allen C, Nakamura T, Zollman P, James CD, Peng KW, Schroeder M, Russell SJ, Galanis E. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas. Mol Ther. 2007 Apr; 15(4):677-86. Epub 2007 Feb 13.
    View PubMed
  73. Sarkaria JN, Yang L, Grogan PT, Kitange GJ, Carlson BL, Schroeder MA, Galanis E, Giannini C, Wu W, Dinca EB, James CD. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther. 2007 Mar; 6(3):1167-74.
    View PubMed
  74. Papagelopoulos PJ, Mavrogenis AF, Galanis EC, Savvidou OD, Inwards CY, Sim FH. Clinicopathological features, diagnosis, and treatment of adamantinoma of the long bones. Orthopedics. 2007 Mar; 30(3):211-5; quiz 216-7.
    View PubMed
  75. Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol. 2007 Feb; 4(2):101-17.
    View PubMed
  76. Allen C, Vongpunsawad S, Nakamura T, James CD, Schroeder M, Cattaneo R, Giannini C, Krempski J, Peng KW, Goble JM, Uhm JH, Russell SJ, Galanis E. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res. 2006 Dec 15; 66(24):11840-50.
    View PubMed
  77. Simpson L, Galanis E. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates. Expert Rev Anticancer Ther. 2006 Nov; 6(11):1593-607.
    View PubMed
  78. McDonald CJ, Erlichman C, Ingle JN, Rosales GA, Allen C, Greiner SM, Harvey ME, Zollman PJ, Russell SJ, Galanis E. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res Treat. 2006 Sep; 99(2):177-84. Epub 2006 Apr 27.
    View PubMed
  79. Papagelopoulos PJ, Savvidou OD, Galanis EC, Mavrogenis AF, Jacofsky DJ, Frassica FJ, Sim FH. Advances and challenges in diagnosis and management of skeletal metastases. Orthopedics. 2006 Jul; 29(7):609-20; quiz 621-2.
    View PubMed
  80. Papagelopoulos PJ, Galanis EC, Mavrogenis AF, Savvidou OD, Bond JR, Unni KK, Sim FH. Survivorship analysis in patients with periosteal chondrosarcoma. Clin Orthop Relat Res. 2006 Jul; 448:199-207.
    View PubMed
  81. Papagelopoulos PJ, Mavrogenis AF, Kelekis AD, Katonis P, Galanis EC, Wenger DE, Sim FH, Soucacos PN. Percutaneous osteoplasty for pelvic and spine metastases. Orthopedics. 2006 Apr; 29(4):316-23.
    View PubMed
  82. Galanis E, Buckner JC, Maurer MJ, Sykora R, Castillo R, Ballman KV, Erickson BJ. Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. Neuro Oncol. 2006 Apr; 8(2):156-65. Epub 2006 Mar 02.
    View PubMed
  83. Papagelopoulos PJ, Mavrogenis AF, Chloros GD, Galanis EC, Papaparaskeva KT. A 60-year-old man with right hip pain. Clin Orthop Relat Res. 2006 Feb; 443:342-9.
    View PubMed
  84. Papagelopoulos PJ, Mavrogenis AF, Mitsiokapa EA, Papaparaskeva KT, Galanis EC, Soucacos PN. Current trends in the management of extra-abdominal desmoid tumours. World J Surg Oncol. 2006; 4:21. Epub 2006 Apr 03.
    View PubMed
  85. Galanis E, Buckner JC, Maurer MJ, Reid JM, Kuffel MJ, Ames MM, Scheithauer BW, Hammack JE, Pipoly G, Kuross SA. Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial. Invest New Drugs. 2005 Oct; 23(5):495-503.
    View PubMed
  86. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ, North Central Cancer Treatment Group. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol. 2005 Aug 10; 23(23):5294-304. Epub 2005 Jul 05.
    View PubMed
  87. Papagelopoulos PJ, Savvidou OD, Mavrogenis AF, Galanis EC, Shaughnessy WJ, Unni KK, Sim FH. Lateral malleolus en bloc resection and ankle reconstruction for malignant tumors. Clin Orthop Relat Res Relat Res. 2005 Aug; (437):209-18.
    View PubMed
  88. Papagelopoulos PJ, Mavrogenis AF, Galanis EC, Kelekis NL, Wenger DE, Sim FH, Soucacos PN. Minimally invasive techniques in orthopedic oncology: Radiofrequency and laser thermal ablation. Orthopedics. 2005 Jun; 28(6):563-8.
    View PubMed
  89. Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL, Schroeder MA, James CD. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol. 2005 Apr; 7(2):164-76.
    View PubMed
  90. Galanis E, Okuno SH, Nascimento AG, Lewis BD, Lee RA, Oliveira AM, Sloan JA, Atherton P, Edmonson JH, Erlichman C, Randlev B, Wang Q, Freeman S, Rubin J. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther. 2005 Mar; 12(5):437-45.
    View PubMed
  91. Papagelopoulos PJ, Mavrogenis AF, Galanis EC, Chloros GD, Papaparaskeva KT. Malignant fibrous histiocytoma of bone associated with type-1 neurofibromatosis. A case report J Bone Joint Surg Am. 2005; 87(2):399-403.
  92. Galanis E, Burch PA, Richardson RL, Lewis B, Pitot HC, Frytak S, Spier C, Akporiaye ET, Peethambaram PP, Kaur JS, Okuno SH, Unni KK, Rubin J. Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma. Cancer. 2004 Dec 1; 101(11):2557-66.
    View PubMed
  93. Papagelopoulos PJ, Mavrogenis AF, Galanis EC, Savvidou OD, Boscainos PJ, Katonis PG, Sim FH. Chordoma of the spine: Clinicopathological features, diagnosis, and treatment. Orthopedics. 2004 Dec; 27(12):1256-63.
    View PubMed
  94. Allen C, McDonald C, Giannini C, Peng KW, Rosales G, Russell SJ, Galanis E. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas. J Gene Med. 2004 Nov; 6(11):1216-27.
    View PubMed
  95. Papagelopoulos PJ, Mavrogenis AF, Currier BL, Katonis P, Galanis EC, Sapkas GS, Korres DS. Primary malignant tumors of the cervical spine. Orthopedics. 2004 Oct; 27(10):1066-75.
    View PubMed
  96. Savvidou OD, Papagelopoulos PJ, Galanis EC, Inwards CY, Wenger DE, Sim FH. Erdheim-Chester disease: a rare lipoid granulomatosis. Orthopedics. 2004; 27(7):1-5.
  97. Peng KW, Frenzke M, Myers R, Soeffker D, Harvey M, Greiner S, Galanis E, Cattaneo R, Federspiel MJ, Russell SJ. Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice. Hum Gene Ther. 2003 Nov 1; 14(16):1565-77.
    View PubMed
  98. Goetz MP, Erlichman C, Windebank AJ, Reid JM, Sloan JA, Atherton P, Adjei AA, Rubin J, Pitot H, Galanis E, Ames MM, Goldberg RM. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol. 2003 Oct 15; 21(20):3761-9. Epub 2003 Sep 08.
    View PubMed
  99. Phuong LK, Allen C, Peng KW, Giannini C, Greiner S, TenEyck CJ, Mishra PK, Macura SI, Russell SJ, Galanis EC. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res. 2003 May 15; 63(10):2462-9.
    View PubMed
  100. Johnson KJ, Peng KW, Allen C, Russell SJ, Galanis E. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction. Gene Ther. 2003 May; 10(9):725-32.
    View PubMed
  101. Papagelopoulos PJ, Savvidou OD, Galanis EC, Wenger DE, Inwards CY, Sim FH. Erdheim-Chester disease. Orthopedics. 2003 May; 26(5):505-8.
    View PubMed
  102. Hamid O, Varterasian ML, Wadler S, Hecht JR, Benson A, Galanis E, Uprichard M, Omer C, Bycott P, Hackman RC, Shields AF. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol. 2003 Apr 15; 21(8):1498-504.
    View PubMed
  103. Mavrogenis AF, Papagelopoulos PJ, Galanis EC, Psicharis IP, Savvidou OD, Karavolias C, Linardaki E. Molecular biology of bone tumors. Ostoun. 2003; 14(2):102-109.
  104. Savvidou OD, Papagelopoulos PJ, Galanis EC, Papdopoulos HC, Boscainos PJ, Karavolias CE. Current concepts on treatment and prognosis of osteosarcoma. Ostoun. 2003; 14(2):110-117.
  105. Papadopoulos EC, Papagelopoulos PJ, Galanis EC, Savvidou OD, Karavolias CE, Mavrogenis AF. Epidemiological data, diagnosis and treatment of Ewing sarcoma. Ostoun. 2003; 14(2):125-131.
  106. Savvidou OD, Papagelopoulos PJ, Galanis EC, Boscainos PJ, Papdopoulos EC, Triantafillopoulos IK. Malignant fibrous histiocytoma of bone. Diagnosis and Treatment. Ostoun. 2003; 14(2):132-139.
  107. Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J, Randlev B, Heise C, Uprichard M, Hatfield M, Rome L, Rubin J, Kirn D. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints. Cancer Res. 2002 Nov 1; 62(21):6070-9.
    View PubMed
  108. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 2002 Aug 15; 62(16):4656-62.
    View PubMed
  109. Papagelopoulos PJ, Galanis EC, Boscainos PJ, Bond JR, Unni KK, Sim FH. Periosteal chondrosarcoma. Orthopedics. 2002 Aug; 25(8):839-42.
    View PubMed
  110. Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E. Phase II trial of gemcitabine in advanced sarcomas. Cancer. 2002 Jun 15; 94(12):3225-9.
    View PubMed
  111. Papagelopoulos PJ, Currier BL, Galanis E, Grubb MJ, Pritchard DJ, Ebersold MJ. Vertebra plana caused by primary Ewing sarcoma: case report and review of the literature. J Spinal Disord Tech. 2002 Jun; 15(3):252-7.
    View PubMed
  112. Papagelopoulos PJ, Galanis EC, Trantafyllidis P, Boscainos PJ, Sim FH, Unni KK. Clinicopathologic features, diagnosis, and treatment of fibrosarcoma of bone. Am J Orthop. 2002 May;31(5):253-7.
    View PubMed
  113. Galanis E. Technology evaluation: Allovectin-7, Vical. Curr Opin Mol Ther. 2002 Feb; 4(1):80-7.
    View PubMed
  114. Galanis E, Russell S. Cancer gene therapy clinical trials: lessons for the future. Br J Cancer. 2001 Nov 16; 85(10):1432-6.
    View PubMed
  115. Reid T, Galanis E, Abbruzzese J, Sze D, Andrews J, Romel L, Hatfield M, Rubin J, Kirn D. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther. 2001 Nov; 8(21):1618-26.
    View PubMed
  116. Galanis E, Vile R, Russell SJ. Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit Rev Oncol Hematol. 2001 Jun; 38(3):177-92.
    View PubMed
  117. Galanis E, Bateman A, Johnson K, Diaz RM, James CD, Vile R, Russell SJ. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum Gene Ther. 2001 May 1; 12(7):811-21.
    View PubMed
  118. Galanis E, Goldberg R, Reid J, Atherton P, Sloan J, Pitot H, Rubin J, Adjei AA, Burch P, Safgren SL, Witzig TE, Ames MM, Erlichman C. Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd). Ann Oncol. 2001 May; 12(5):701-7.
    View PubMed
  119. Daniels GA, Galanis E. Immunotherapy of renal cell carcinoma by intratumoral administration of an IL-2 cDNA/DMRIE/DOPE lipid complex. Curr Opin Mol Ther. 2001 Feb; 3(1):70-6.
    View PubMed
  120. Galanis E, Buckner JC. Chemotherapy of brain tumors. Curr Opin Neurol. 2000 Dec; 13(6):619-25.
    View PubMed
  121. Galanis E, Alberts SR, O'Connell MJ. New adjuvant therapy for colon cancer: justified hope or commercial hype. Surg Oncol Clin N Am. 2000 Oct; 9(4):813-23; discussion 825-6.
    View PubMed
  122. Galanis E, Buckner JC, Novotny P, Morton RF, McGinnis WL, Dinapoli R, Schomberg P, O'Fallon JR. Efficacy of neuroradiological imaging, neurological examination, and symptom status in follow-up assessment of patients with high-grade gliomas. J Neurosurg. 2000 Aug; 93(2):201-7.
    View PubMed
  123. Galanis E, Buckner J. Chemotherapy for high-grade gliomas. Br J Cancer. 2000 Apr; 82(8):1371-80.
    View PubMed
  124. Papagelopoulos PJ, Galanis E, Frassica FJ, Sim FH, Larson DR, Wold LE. Primary fibrosarcoma of bone. Outcome after primary surgical treatment. Clin Orthop Relat Res. 2000 Apr; (373):88-103.
    View PubMed
  125. Papagelopoulos PJ, Galanis EC, Sim FH, Unni KK. Clinicopathologic features, diagnosis, and treatment of malignant fibrous histiocytoma of bone. Orthopedics (Thorofare, NJ). 2000 Jan; 23(1):59-65; quiz 66-7.
    View PubMed
  126. Galanis E, Rubin J. Intratumoral Gene Transfer of the HLA-B7 Gene Into Colon Carcinoma Metastases. Methods Mol Med. 2000; 35:453-67.
    View PubMed
  127. Papagelopoulos PJ, Galanis E, Vlastou C, Nikiforidis PA, Vlamis JA, Boscainos PJ, Fragiadakis EG, Stamos KG, Pantazopoulos T, Sim FH. Current concepts in the evaluation and treatment of osteosarcoma. Orthopedics. 2000; 23:858-67.
    View PubMed
  128. Galanis E, Hersh EM, Stopeck AT, Gonzalez R, Burch P, Spier C, Akporiaye ET, Rinehart JJ, Edmonson J, Sobol RE, Forscher C, Sondak VK, Lewis BD, Unger EC, O'Driscoll M, Selk L, Rubin J. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. J Clin Oncol. 1999 Oct; 17(10):3313-23.
    View PubMed
  129. James CD, Galanis E, Frederick L, Kimmel DW, Cunningham JM, Atherton-Skaff PJ, O'Fallon JR, Jenkins RB, Buckner JC, Hunter SB, Olson JJ, Scheithauer BW. Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluation. Int J Oncol. 1999 Sep; 15(3):547-53.
    View PubMed
  130. Galanis E, Frytak S, Rowland KM Jr, Sloan JA, Lennon VA. Neuronal autoantibody titers in the course of small-cell lung carcinoma and platinum-associated neuropathy. Cancer Immunol Immunother. 1999 May-Jun; 48(2-3):85-90.
    View PubMed
  131. Papagelopoulos PJ, Currier BL, Galanis EC, Sim FH. Vertebra plana of the lumbar spine caused by an aneurysmal bone cyst: a case report. Am J Orthop (Belle Mead NJ) 1999 Feb; 28(2):119-24.
    View PubMed
  132. Papagelopoulos PJ, Galanis EC, Sim FH, Unni KK. Clinicopathologic features, diagnosis, and treatment of osteoblastoma. Orthopedics. 1999 Feb; 22(2):244-7; quiz 248-9.
    View PubMed
  133. Papagelopoulos PJ, Galanis E, Sim FH, Unni KK. Mayo Clinic tumor rounds: periosteal osteosarcoma. Orthopedics. 1999; 22(10):971-974.
    View PubMed
  134. Papagelopoulos PJ, Galanis E, Sim FH, Unni KK. Periosteal osteosarcoma. Orthopedics. 1999; 10:971-4.
  135. Galanis E, Buckner J, Kimmel D, Jenkins R, Alderete B, O'Fallon J, Wang CH, Scheithauer BW, James CD. Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas. Int J Oncol. 1998 Oct; 13(4):717-24.
    View PubMed
  136. Galanis E, Buckner JC, Burch PA, Schaefer PL, Dinapoli RP, Novotny PJ, Scheithauer BW, Rowland KM, Vukov AM, Mailliard JA, Morton RF. Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results. J Clin Oncol. 1998 Sep; 16(9):2953-8.
    View PubMed
  137. Galanis E, Buckner JC, Dinapoli RP, Scheithauer BW, Jenkins RB, Wang CH, O'Fallon JR, Farr G Jr. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results. J Neurosurg. 1998 Sep; 89(3):425-30.
    View PubMed
  138. Galanis E, Buckner JC, Scheithauer BW, Kimmel DW, Schomberg PJ, Piepgras DG. Management of recurrent meningeal hemangiopericytoma. Cancer. 1998 May 15; 82(10):1915-20.
    View PubMed
  139. Papagelopoulos PJ, Galanis EC, Sim FH, Unni KK. Osteoblastoma of the acetabulum. Orthopedics. 1998 Mar; 21(3):355-8.
    View PubMed
  140. Galanis E, Kvols LK, Rubin J. Carcinoid syndrome. J Clin Oncol. 1998 Feb; 16(2):796-8.
    View PubMed
  141. Galanis E. Cancer gene therapy: an overview based on the first annual meeting of the American Society of Gene Therapy. Tumor Targeting. 1998; 3(3):191-194.
  142. Skarin A, Galanis E, Kvols LK, Rubin J. Diagnosis in oncology. J Clin Oncol. 1998; 16(2):796-798.
  143. Papagelopoulos P, Galanis E, Sim F, Unni K Mayo Clinic tumor rounds - osteoblastoma of the acetabulum. Orthopedics. 1998; 21(3):355-358.
    View PubMed
  144. Galanis E, Hartmann LC. Granulocyte colony-stimulating factor in severe chemotherapy induced afebrile neutropenia. Topics Support Care Oncol. 1998; 26:12-3.
  145. Galanis E, Litzow MR, Tefferi A, Scott JP. Spontaneous pneumomediastinum in a patient with bronchiolitis obliterans after bone marrow transplantation. Bone Marrow Transplant. 1997 Oct; 20(8):695-6.
    View PubMed
  146. Papagelopoulos PJ, Galanis EC, Greipp PR, Sim FH. Prosthetic hip replacement for pathologic or impending pathologic fractures in myeloma. Clin Orthop. 1997 Aug; 341:192-205.
    View PubMed
  147. Galanis E, Buckner JC, Schomberg PJ, Hammack JE, Raffel C, Scheithauer BW. Effective chemotherapy for advanced CNS embryonal tumors in adults. J Clin Oncol. 1997 Aug; 15(8):2939-44.
    View PubMed
  148. Galanis E, Frytak S, Lloyd RV. Extrapulmonary small cell carcinoma. Cancer. 1997 May 1; 79(9):1729-36.
    View PubMed
  149. Rubin J, Galanis E, Pitot HC, Richardson RL, Burch PA, Charboneau JW, Reading CC, Lewis BD, Stahl S, Akporiaye ET, Harris DT. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Gene Ther. 1997 May; 4(5):419-25.
    View PubMed
  150. Papagelopoulos PJ, Hay JE, Galanis EC, Morrey BF. Total joint arthroplasty in orthotopic liver transplant recipients. J Arthroplasty. 1996 Dec; 11(8):889-92.
    View PubMed
  151. Papagelopoulos P, Galanis E, Shaughnessy WJ, Currier BL, Sim FH, Unni KK. Aneurysmal bone cysts of the cervical spine. Acta Orthopaedica Hellenica. 1994; 45(4):214-223.
  152. Galanis E. Infectious endocarditis: Prognosis, prophylaxis, treatment. Topics in Cardiology. 1989; 83.